These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31418127)

  • 21. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in Therapeutic Genome Editing in China.
    Yang Y; Wang Q; Li Q; Men K; He Z; Deng H; Ji W; Wei Y
    Hum Gene Ther; 2018 Feb; 29(2):136-145. PubMed ID: 29446996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in CRISPR/Cas9-Mediated Genome Editing in
    Muramoto T; Iriki H; Watanabe J; Kawata T
    Cells; 2019 Jan; 8(1):. PubMed ID: 30642074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
    Dong W; Kantor B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene editing based hearing impairment research and therapeutics.
    Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
    Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induced mutation and epigenetics modification in plants for crop improvement by targeting CRISPR/Cas9 technology.
    Khan MHU; Khan SU; Muhammad A; Hu L; Yang Y; Fan C
    J Cell Physiol; 2018 Jun; 233(6):4578-4594. PubMed ID: 29194606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing.
    Liu B; Chen S; Rose A; Chen D; Cao F; Zwinderman M; Kiemel D; Aïssi M; Dekker FJ; Haisma HJ
    Nucleic Acids Res; 2020 Jan; 48(2):517-532. PubMed ID: 31799598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides.
    Ding X; Seebeck T; Feng Y; Jiang Y; Davis GD; Chen F
    CRISPR J; 2019 Feb; 2():51-63. PubMed ID: 31021236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of CRISPR Tools for Variant Interpretation and Disease Modeling in Inherited Retinal Dystrophies.
    Fuster-García C; García-Bohórquez B; Rodríguez-Muñoz A; Millán JM; García-García G
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32349249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.
    Mehravar M; Roshandel E; Salimi M; Chegeni R; Gholizadeh M; Mohammadi MH; Hajifathali A
    Immunol Lett; 2020 Oct; 226():71-82. PubMed ID: 32687855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations.
    Memi F; Ntokou A; Papangeli I
    Semin Perinatol; 2018 Dec; 42(8):487-500. PubMed ID: 30482590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
    Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
    J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Directed Evolution of CRISPR-Cas9 Base Editors.
    Winter J; Perez-Pinera P
    Trends Biotechnol; 2019 Nov; 37(11):1151-1153. PubMed ID: 31623959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
    Tao Y; Yi K; Hu H; Shao D; Li M
    J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.